StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Braftovi + Mektovi (encorafenib / binimetinib by Year

Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Braftovi + Mektovi (encorafenib / binimetinib: $716M in FY2025, up 18.0% from a year earlier.

Latest, FY2025
716
Period ended Dec 31, 2025
Change on a year earlier
+18.0%
607 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Braftovi/Mektovi | 716 | 607 | 18% | 18% | 672 | 580 | 16% | 45 | 27 | 67% | 71%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBraftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025716+18.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024607+27.3%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023477+4.6%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022456–Form 10-K (filed 2025-02-27) ↗

Breakdown

What makes up braftovi + Mektovi (encorafenib / binimetinib

Cite this data

StockData. (2026). Pfizer Braftovi + Mektovi (encorafenib / binimetinib ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/braftovi-mektovi-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.